Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Cost of living payment date brought forward
...
Read moreDetailsHome » Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.